Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.47 |
| ▸ | CES1 | P23141 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | CTSG | P08311 | 3/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.47 |
| ▸ | CMA1 | P23946 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248513 | 0.95 | LCK (0.55) | CES2CES1LCKPPARDZDHHC20 | |
| SCHEMBL2871593 | 0.93 | LCK (0.58) | CES2CES1LCKPPARDZDHHC20 | |
| SCHEMBL11754693 | 0.93 | LCK (0.58) | CES2CES1LCKPPARDZDHHC20 | |
| SCHEMBL2823791 | 0.89 | SLC6A2 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL4935875 | 0.89 | SLC6A2 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL27527322 | 0.84 | HSD17B3 (0.51) | LCKPPARDZDHHC20ZDHHC2SLC6A2 | |
| SCHEMBL10467094 | 0.83 | MMP2 (0.48) | CES2CES1LCKPPARDZDHHC20 | |
| SCHEMBL12475594 | 0.81 | MMP2 (0.55) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL504212 | 0.81 | MDM2 (0.53) | CES2CES1PRSS1CTSGCTRB1 | |
| SCHEMBL634150 | 0.81 | ALDH1A1 (0.51) | SLC6A2SLC6A3HRH1KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246973-A1 | Cathinone Derivatives, Pharmaceutical Formulations, and Methods | THE CORPORATION OF MERCER UNIVERSITY | 2024-07-25 | — | — | US | disclosed |
| US-11912705-B2 | Cathinone derivatives, pharmaceutical formulations, and methods | THE CORPORATION OF MERCER UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912705-B2 | Cathinone derivatives, pharmaceutical formulations, and methods | THE CORPORATION OF MERCER UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220056029-A1 | Cathinone Derivatives, Pharmaceutical Formulations, and Methods | THE CORPORATION OF MERCER UNIVERSITY | 2022-02-24 | — | — | US | disclosed |
| US-8778948-B2 | Substituted phenylpiperazinyl aralkylalcohol derivatives, pharmaceutical compositions containing such derivatives and uses thereof | NHWA Pharma, Corporation (CN) | 2014-07-15 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | NHWA PHARMA. CORPORATION (CN) | 2011-12-01 | — | — | US | disclosed |
| EP-1322309-B1 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| WO-2005035540-A2 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG-SIPSY (FR) | 2005-04-21 | — | — | WO | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1322309-A4 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1322309-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002049993-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | disclosed |
| US-4103023-A | ANTIULCER, 3,3A,6,6A-TETRAHYDROFURO(3,4-B)FURAN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | CES2 4777/4885CES1 3590/4885LCK 787/4885 |
| US-20220056029-A1 | Cathinone Derivatives, Pharmaceutical Formulations, and Methods | TACR2, TACR1, ADRA2C | CES2 193/4885CES1 1245/4885LCK 2283/4885 |
| US-20240246973-A1 | Cathinone Derivatives, Pharmaceutical Formulations, and Methods | TACR2, TACR1, ADRA2C | CES2 193/4885CES1 1245/4885LCK 2283/4885 |
| US-11912705-B2 | Cathinone derivatives, pharmaceutical formulations, and methods | TACR2, TACR1, ADRA2C | CES2 193/4885CES1 1245/4885LCK 2283/4885 |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | OPRL1, OPRK1, OPRD1 | CES2 762/4885CES1 1605/4885LCK 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.